Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.42 |
| ▸ | SNCA | P37840 | 2/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991623 | 0.98 | HIF1A (0.64) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL25208717 | 0.95 | HIF1A (0.61) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL9810148 | 0.93 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2743878 | 0.91 | HIF1A (0.56) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL18641785 | 0.91 | HIF1A (0.56) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL9817056 | 0.91 | HIF1A (0.56) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL16197577 | 0.91 | HIF1A (0.56) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL35210203 | 0.91 | HIF1A (0.56) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL15918268 | 0.91 | HIF1A (0.56) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL35210196 | 0.89 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745126-A1 | PESTICIDALLY-ACTIVE 2,2-DIHALOCYCLOPROPYL COMPOUNDS | Syngenta Crop Protection AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735417-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | Shanghai Vitalgen Biopharma Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12616753-B2 | HSP70 inhibitors and methods of using same | THE WISTAR INSTITUTE (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2025235840-A1 | ECHINOCANDIN-LIKE AND BORON-CONTAINING ECHINOCANDIN COMPOUNDS AND THEIR USE AS AGROCHEMICAL FUNGICIDES | 5METIS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250057785-A1 | APPLICATION OF 10'(Z), 13'(E), 15'(E)-HEPTADECATRIENYL HYDROQUINONE (HQ17(3)) IN TREATING CORONAVIRUS INFECTION | NATIONAL ATOMIC RESEARCH INSTITUTE (TW) | 2025-02-20 | — | — | US | disclosed |
| EP-4489855-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2025000542-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SHANGHAI VITALGEN BIOPHARMA CO., LTD. (CN) | 2025-01-02 | — | — | WO | disclosed |
| US-4853381-A | Ethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| US-4853382-A | TREATING ASTHMA AND BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| EP-0178919-B1 | AMINOPHENOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1988-12-21 | — | — | EP | disclosed |
| US-4730008-A | STIMULANT FOR BETA-ADRENORECEPTORS | GLAXO GROUP LIMITED (GB) | 1988-03-08 | — | — | US | disclosed |
| EP-0223410-A2 | Ethanolamine Derivatives | GLAXO GROUP LIMITED (GB) | 1987-05-27 | — | — | EP | disclosed |
| EP-0220054-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
| EP-0178919-A2 | Aminophenol derivatives | GLAXO GROUP LIMITED (GB) | 1986-04-23 | — | — | EP | disclosed |
| US-4432906-A | ANTIALLERGENS, BRONCHODILATOR | HOFFMANN-LA ROCHE INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4201874-A | 3-Isopropenyl-6-heptenoic acid | ZOECON CORPORATION (US) | 1980-05-06 | — | — | US | disclosed |
| US-4169860-A | INSECT PHEROMONE | ZOECON CORPORATION (US) | 1979-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616753-B2 | HSP70 inhibitors and methods of using same | HSPB1, HSP90AB1, HSF1 | HIF1A 1512/4885ALDH1A1 1076/4885CYP1A2 3513/4885 |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | HIF1A 982/4885ALDH1A1 2596/4885CYP1A2 4345/4885 |
| US-20250057785-A1 | APPLICATION OF 10'(Z), 13'(E), 15'(E)-HEPTADECATRIENYL HYDROQUINONE (HQ17(3)) IN TREATING CORONAVIRUS INFECTION | IL17A, ACE2, HSD17B13 | HIF1A 1260/4885ALDH1A1 1000/4885CYP1A2 121/4885 |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | GLP1R, GIPR, GCGR | HIF1A 982/4885ALDH1A1 2596/4885CYP1A2 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.